Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating urinary bladder condition that presents with a wide variety of clinical phenotypes. It is commonly characterized by persistent pelvic pain and lower urinary tract symptoms, such as urinary frequency and urgency. Current clinicopa...

Full description

Bibliographic Details
Main Author: Yoshiyuki Akiyama
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/11/12/2238
_version_ 1797505503685771264
author Yoshiyuki Akiyama
author_facet Yoshiyuki Akiyama
author_sort Yoshiyuki Akiyama
collection DOAJ
description Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating urinary bladder condition that presents with a wide variety of clinical phenotypes. It is commonly characterized by persistent pelvic pain and lower urinary tract symptoms, such as urinary frequency and urgency. Current clinicopathological and genomic evidence has indicated that IC/BPS with Hunner lesions is a clinically relevant distinct subtype with proven bladder pathology of subepithelial chronic inflammatory changes that are characterized by enhanced local immune responses and epithelial denudation. However, other forms of IC/BPS lacking Hunner lesions are a symptom syndrome complex of non-inflammatory conditions with little evidence of bladder etiology, characterized by aberrant neural activity in neurotransmission systems which leads to central nervous sensitization with potential involvement of urothelial malfunction, or clinical presentation of somatic and/or psychological symptoms beyond the bladder. Given such distinct potential pathophysiology between IC/BPS subtypes, disease biomarkers of IC/BPS should be provided separately for subtypes with and without Hunner lesions. Tailored approaches that target characteristic immunological inflammatory processes and epithelial denudation for IC/BPS with Hunner lesions, or the sensitized/altered nervous system, urothelial malfunction, association with other functional somatic syndromes, and psychosocial problems for IC/BPS without Hunner lesions, are essential to identify optimal and reliable disease-specific IC/BPS biomarkers.
first_indexed 2024-03-10T04:19:31Z
format Article
id doaj.art-fa1e94d6af74447bb494adf9fad0fd7d
institution Directory Open Access Journal
issn 2075-4418
language English
last_indexed 2024-03-10T04:19:31Z
publishDate 2021-11-01
publisher MDPI AG
record_format Article
series Diagnostics
spelling doaj.art-fa1e94d6af74447bb494adf9fad0fd7d2023-11-23T07:53:20ZengMDPI AGDiagnostics2075-44182021-11-011112223810.3390/diagnostics11122238Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future PerspectivesYoshiyuki Akiyama0Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 1138655, JapanInterstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating urinary bladder condition that presents with a wide variety of clinical phenotypes. It is commonly characterized by persistent pelvic pain and lower urinary tract symptoms, such as urinary frequency and urgency. Current clinicopathological and genomic evidence has indicated that IC/BPS with Hunner lesions is a clinically relevant distinct subtype with proven bladder pathology of subepithelial chronic inflammatory changes that are characterized by enhanced local immune responses and epithelial denudation. However, other forms of IC/BPS lacking Hunner lesions are a symptom syndrome complex of non-inflammatory conditions with little evidence of bladder etiology, characterized by aberrant neural activity in neurotransmission systems which leads to central nervous sensitization with potential involvement of urothelial malfunction, or clinical presentation of somatic and/or psychological symptoms beyond the bladder. Given such distinct potential pathophysiology between IC/BPS subtypes, disease biomarkers of IC/BPS should be provided separately for subtypes with and without Hunner lesions. Tailored approaches that target characteristic immunological inflammatory processes and epithelial denudation for IC/BPS with Hunner lesions, or the sensitized/altered nervous system, urothelial malfunction, association with other functional somatic syndromes, and psychosocial problems for IC/BPS without Hunner lesions, are essential to identify optimal and reliable disease-specific IC/BPS biomarkers.https://www.mdpi.com/2075-4418/11/12/2238interstitial cystitisbladder pain syndromeIC/BPSPBSbiomarker
spellingShingle Yoshiyuki Akiyama
Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives
Diagnostics
interstitial cystitis
bladder pain syndrome
IC/BPS
PBS
biomarker
title Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives
title_full Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives
title_fullStr Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives
title_full_unstemmed Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives
title_short Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives
title_sort biomarkers in interstitial cystitis bladder pain syndrome with and without hunner lesion a review and future perspectives
topic interstitial cystitis
bladder pain syndrome
IC/BPS
PBS
biomarker
url https://www.mdpi.com/2075-4418/11/12/2238
work_keys_str_mv AT yoshiyukiakiyama biomarkersininterstitialcystitisbladderpainsyndromewithandwithouthunnerlesionareviewandfutureperspectives